## Alexandre de Mendonça

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2628119/publications.pdf

Version: 2024-02-01

182 papers

11,156 citations

53 h-index 97 g-index

184 all docs

184 docs citations

184 times ranked

12661 citing authors

#	Article	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
2	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
3	Adenosine receptors in the nervous system: pathophysiological implications. Progress in Neurobiology, 2002, 68, 377-392.	2.8	452
4	The neuroprotective effects of caffeine. Neurology, 2007, 69, 536-545.	1.5	320
5	Does caffeine intake protect from Alzheimer's disease?. European Journal of Neurology, 2002, 9, 377-382.	1.7	317
6	Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests. BMC Research Notes, 2011, 4, 299.	0.6	284
7	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	3.7	284
8	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	5.8	263
9	A Panâ€xscp>European Study of the <i>C9orf72</i> Repeat Associated with <scp>FTLD</scp> : Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	1.1	247
10	Adenosine A2A receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and "fine tuning―modulation. Progress in Neurobiology, 2007, 83, 310-331.	2.8	232
11	Adenosine: does it have a neuroprotective role after all?. Brain Research Reviews, 2000, 33, 258-274.	9.1	224
12	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	1.2	197
13	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.4	179
14	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
15	Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. NeuroReport, 1995, 6, 1097-1100.	0.6	153
16	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	1.5	151
17	Enhanced role of adenosine A2A receptors in the modulation of LTP in the rat hippocampus upon ageing. European Journal of Neuroscience, 2011, 34, 12-21.	1.2	149
18	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140

#	Article	IF	Citations
19	Association of Cerebral Amyloid- $\hat{l}^2$ Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
20	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	4.9	128
21	Quality of life in patients with mild cognitive impairment. Aging and Mental Health, 2013, 17, 287-292.	1.5	126
22	Endogenous adenosine modulates long-term potentiation in the hippocampus. Neuroscience, 1994, 62, 385-390.	1.1	121
23	Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. European Journal of Neuroscience, 2003, 18, 820-828.	1.2	108
24	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- $\hat{l}^2$ in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	3.7	107
25	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	0.9	106
26	Assessment of dementia in ethnic minority patients in Europe: a European Alzheimer's Disease Consortium survey. International Psychogeriatrics, 2011, 23, 86-95.	0.6	104
27	Caffeine, Adenosine Receptors, and Synaptic Plasticity. Journal of Alzheimer's Disease, 2010, 20, S25-S34.	1.2	101
28	Enhanced Adenosine A2A Receptor Facilitation of Synaptic Transmission in the Hippocampus of Aged Rats. Journal of Neurophysiology, 2003, 90, 1295-1303.	0.9	97
29	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
30	Memory complaints in healthy young and elderly adults: Reliability of memory reporting. Aging and Mental Health, 2008, 12, 177-182.	1.5	96
31	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	3.9	93
32	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	1.1	87
33	Verbal learning and memory deficits in Mild Cognitive Impairment. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 187-197.	0.8	85
34	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
35	Adenosine and neuronal plasticity. Life Sciences, 1996, 60, 245-251.	2.0	84
36	Caffeine Intake is Associated with a Lower Risk of Cognitive Decline: A Cohort Study from Portugal. Journal of Alzheimer's Disease, 2010, 20, S175-S185.	1.2	83

#	Article	IF	Citations
37	Functional evaluation distinguishes MCI patients from healthy elderly people — The ADCS/MCI/ADL scale. Journal of Nutrition, Health and Aging, 2010, 14, 703-709.	1.5	83
38	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. Acta Neuropathologica, 2016, 132, 213-224.	3.9	83
39	Memory Complaints Are Frequent but Qualitatively Different in Young and Elderly Healthy People. Gerontology, 2010, 56, 272-277.	1.4	77
40	Participation of adenosine receptors in neuroprotection. Drug News and Perspectives, 2003, 16, 80.	1.9	77
41	Mild Cognitive Impairment: Deficits in Cognitive Domains Other than Memory. Dementia and Geriatric Cognitive Disorders, 2006, 21, 284-290.	0.7	74
42	Endogenous Adenosine Attenuates Long-term Depression and Depotentiation in the CA1 Region of the Rat Hippocampus. Neuropharmacology, 1997, 36, 161-167.	2.0	73
43	Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice. Neuroscience, 2012, 220, 256-266.	1.1	73
44	Genetic and biochemical markers in patients with Alzheimer's disease support a concerted systemic iron homeostasis dysregulation. Neurobiology of Aging, 2014, 35, 777-785.	1.5	68
45	Adenosine modulates synaptic plasticity in hippocampal slices from aged rats. Brain Research, 1999, 851, 228-234.	1.1	66
46	Hypoxia-induced desensitization and internalization of adenosine A1 receptors in the rat hippocampus. Neuroscience, 2006, 138, 1195-1203.	1.1	65
47	Adenosine inhibits the NMDA receptor-mediated excitatory postsynaptic potential in the hippocampus. Brain Research, 1993, 606, 351-356.	1.1	64
48	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	1.4	63
49	Magnetic stimulation in Alzheimer's disease. Journal of Neurology, 1997, 244, 304-307.	1.8	60
50	Influence of personality on caregiver's burden, depression and distress related to the BPSD. International Journal of Geriatric Psychiatry, 2011, 26, 1275-1282.	1.3	57
51	Chocolate Consumption is Associated with a Lower Risk of Cognitive Decline. Journal of Alzheimer's Disease, 2016, 53, 85-93.	1.2	57
52	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.4	56
53	Comparison of Four Verbal Memory Tests for the Diagnosis and Predictive Value of Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders Extra, 2012, 2, 120-131.	0.6	55
54	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	3.7	55

#	Article	IF	CITATIONS
55	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 612-621.	0.9	55
56	Purinergic P2 receptors trigger adenosine release leading to adenosine A2A receptor activation and facilitation of long-term potentiation in rat hippocampal slices. Neuroscience, 2003, 122, 111-121.	1.1	53
57	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. Acta Neuropathologica, 2017, 134, 475-487.	3.9	53
58	2-Chloroadenosine decreases long-term potentiation in the hippocampal CA1 area of the rat. Neuroscience Letters, 1990, 118, 107-111.	1.0	49
59	Presynaptic inhibitory receptors mediate the depression of synaptic transmission upon hypoxia in rat hippocampal slices. Brain Research, 2000, 869, 158-165.	1.1	48
60	Does caffeine modify corticomotor excitability?. Neurophysiologie Clinique, 2006, 36, 219-226.	1.0	48
61	A functional role for adenosine A3 receptors: modulation of synaptic plasticity in the rat hippocampus. Neuroscience Letters, 2001, 302, 53-57.	1.0	46
62	Adenosine promotes neuronal recovery from reactive oxygen species induced lesion in rat hippocampal slices. Neuroscience Letters, 2003, 339, 127-130.	1.0	43
63	Clinical significance of subcortical vascular disease in patients with mild cognitive impairment. European Journal of Neurology, 2005, 12, 125-130.	1.7	43
64	The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. European Journal of Neurology, 2011, 18, 279-285.	1.7	42
65	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	2.8	42
66	Adenosine and synaptic plasticity. Drug Development Research, 2001, 52, 283-290.	1.4	41
67	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain, 2019, 142, 1108-1120.	3.7	41
68	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	1.5	40
69	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	1.7	39
70	Long-term potentiation observed upon blockade of adenosine A1 receptors in rat hippocampus is N-methyl-d-aspartate receptor-dependent. Neuroscience Letters, 2000, 291, 81-84.	1.0	38
71	Speech Therapy in Primary Progressive Aphasia: A Pilot Study. Dementia and Geriatric Cognitive Disorders Extra, 2012, 2, 321-331.	0.6	37
72	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	1.1	36

#	Article	IF	Citations
73	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.4	36
74	The Outcome of Elderly Patients with Cognitive Complaints but Normal Neuropsychological Tests. Journal of Alzheimer's Disease, 2010, 19, 137-145.	1.2	35
<b>7</b> 5	Serial position effects in Alzheimer's disease, mild cognitive impairment, and normal aging: Predictive value for conversion to dementia. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 841-852.	0.8	35
76	Quality of life in patients with cognitive impairment: validation of the Quality of Life–Alzheimer's Disease scale in Portugal. International Psychogeriatrics, 2013, 25, 1085-1096.	0.6	35
77	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	1.5	34
78	Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease: a feature selection ensemble combining stability and predictability. BMC Medical Informatics and Decision Making, 2018, 18, 137.	1.5	34
79	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimer's Research and Therapy, 2018, 10, 46.	3.0	34
80	Decrease in APP and CP mRNA expression supports impairment of iron export in Alzheimer's disease patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2116-2122.	1.8	33
81	Predicting progression of mild cognitive impairment to dementia using neuropsychological data: a supervised learning approach using time windows. BMC Medical Informatics and Decision Making, 2017, 17, 110.	1.5	33
82	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. Neurolmage, 2019, 189, 645-654.	2.1	33
83	Online information and support for carers of people with youngâ€onset dementia: A multiâ€site randomised controlled pilot study. International Journal of Geriatric Psychiatry, 2019, 34, 1455-1464.	1.3	33
84	1,3-Dipropyl-8-cyclopentylxanthine attenuates the NMDA response to hypoxia in the rat hippocampus. Brain Research, 1994, 661, 265-273.	1.1	32
85	Adenosine by activating A1 receptors prevents GABAA-mediated actions during hypoxia in the rat hippocampus. Brain Research, 1996, 732, 261-266.	1.1	31
86	Significance of Subjective Memory Complaints in the Clinical Setting. Journal of Geriatric Psychiatry and Neurology, 2014, 27, 259-265.	1.2	31
87	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.4	31
88	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31
89	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. Brain, 2023, 146, 321-336.	3.7	30
90	Influence of metabotropic glutamate receptor agonists on the inhibitory effects of adenosine A1 receptor activation in the rat hippocampus. British Journal of Pharmacology, 1997, 121, 1541-1548.	2.7	29

#	Article	IF	CITATIONS
91	Therapeutic Opportunities for Caffeine in Alzheimer's Disease and Other Neurodegenerative Disorders. Journal of Alzheimer's Disease, 2010, 20, S1-S2.	1.2	28
92	Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort. Journal of Alzheimer's Disease, 2018, 65, 1-16.	1.2	28
93	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	1.4	28
94	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
95	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. Neurolmage: Clinical, 2019, 24, 102077.	1.4	27
96	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	3.7	27
97	An Adenosine Analogue Inhibits NMDA Receptor-Mediated Responses in Bipolar Cells of the Rat Retina. Experimental Eye Research, 1999, 68, 367-370.	1.2	26
98	Nonâ€literal language deficits in mild cognitive impairment. Psychogeriatrics, 2014, 14, 222-228.	0.6	26
99	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	1.1	26
100	Memory Complaints Associated with Seeking Clinical Care. International Journal of Alzheimer's Disease, 2012, 2012, 1-5.	1.1	25
101	Enhanced LTP in aged rats: Detrimental or compensatory?. Neuropharmacology, 2017, 114, 12-19.	2.0	25
102	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	0.9	25
103	RHAPSODY – Internet-based support for caregivers of people with young onset dementia: program design and methods of a pilot study. International Psychogeriatrics, 2016, 28, 2091-2099.	0.6	24
104	Rare Variants in <i>PLD3 </i> Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Human Mutation, 2015, 36, 1226-1235.	1.1	23
105	Education modulates brain maintenance in presymptomatic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1124-1130.	0.9	23
106	Prediction of Long-Term (5 Years) Conversion to Dementia Using Neuropsychological Tests in a Memory Clinic Setting. Journal of Alzheimer's Disease, 2013, 34, 681-689.	1.2	21
107	Education modifies the type of subjective memory complaints in older people. International Journal of Geriatric Psychiatry, 2016, 31, 153-160.	1.3	21
108	Can 11C-PiB-PET Relative Delivery R1 or 11C-PiB-PET Perfusion Replace 18F-FDG-PET in the Assessment of Brain Neurodegeneration?. Journal of Alzheimer's Disease, 2018, 65, 89-97.	1.2	21

#	Article	IF	Citations
109	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp> : A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
110	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	1.5	20
111	Enhancing prospective memory in mild cognitive impairment: The role of enactment. Journal of Clinical and Experimental Neuropsychology, 2015, 37, 863-877.	0.8	19
112	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	1.5	19
113	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	0.9	19
114	Ventricular volume expansion in presymptomatic genetic frontotemporal dementia. Neurology, 2019, 93, e1699-e1706.	1.5	19
115	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	2.8	19
116	Persistence of the neuromodulatory effects of adenosine on synaptic transmission after long-term potentiation and long-term depression. Brain Research, 2002, 932, 56-60.	1.1	18
117	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). Neurolmage: Clinical, 2019, 23, 101846.	1.4	18
118	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	0.7	18
119	Effects of Carbamazepine and Novel 10,11-Dihydro-5H -Dibenz[b,f]Azepine-5-Carboxamide Derivatives on Synaptic Transmission in Rat Hippocampal Slices. Basic and Clinical Pharmacology and Toxicology, 2002, 90, 208-213.	0.0	17
120	Interaction Between P2X and Nicotinic Acetylcholine Receptors in Glutamate Nerve Terminals of the Rat Hippocampus. Journal of Molecular Neuroscience, 2006, 30, 173-176.	1.1	17
121	Electrophysiological Studies in Healthy Subjects Involving Caffeine. Journal of Alzheimer's Disease, 2010, 20, S63-S69.	1.2	17
122	Time Perception in Mild Cognitive Impairment: Interval Length and Subjective Passage of Time. Journal of the International Neuropsychological Society, 2016, 22, 755-764.	1.2	16
123	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	1.5	16
124	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. NeuroImage, 2019, 188, 282-290.	2.1	16
125	Mild Cognitive Impairment: Focus on Diagnosis. Journal of Molecular Neuroscience, 2004, 23, 143-148.	1.1	15
126	Delay discounting in mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology, 2017, 39, 336-346.	0.8	15

#	Article	IF	CITATIONS
127	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	1.5	15
128	Neuropsychological Predictors of Long-Term (10 Years) Mild Cognitive Impairment Stability. Journal of Alzheimer's Disease, 2018, 62, 1703-1711.	1.2	14
129	Classification of primary progressive aphasia: Do unsupervised data mining methods support a logopenic variant?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 147-159.	1.1	13
130	Depression with melancholic features is associated with higher long-term risk for dementia. Journal of Affective Disorders, 2016, 202, 220-229.	2.0	13
131	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
132	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1325-1328.	0.9	12
133	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	3.0	12
134	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72 &lt; /i&gt; -associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.</i>	0.9	12
135	Cognitive deficits in middleâ€aged and older adults with bipolar disorder and cognitive complaints: Comparison with mild cognitive impairment. International Journal of Geriatric Psychiatry, 2009, 24, 624-631.	1.3	11
136	Rapidly progressive frontotemporal dementia and bulbar amyotrophic lateral sclerosis in Portuguese patients with C9orf72 mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 70-72.	1.1	11
137	Neuropsychological profile of amyloidâ€positive versus amyloidâ€negative amnestic Mild Cognitive Impairment. Journal of Neuropsychology, 2021, 15, 41-52.	0.6	11
138	Neuroprotection during hypoxic insults: Role of adenosine. Drug Development Research, 2001, 52, 291-295.	1.4	10
139	Adenosine receptor interactions in the hippocampus. Drug Development Research, 2001, 52, 337-345.	1.4	10
140	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 608-616.	0.9	10
141	Phenotypic Variability of Familial and Sporadic Progranulin p.Gln257Profs*27 Mutation. Journal of Alzheimer's Disease, 2013, 37, 335-342.	1.2	9
142	Personality of the caregiver influences the use of strategies to deal with the behavior of persons with dementia. Geriatric Nursing, 2017, 38, 63-69.	0.9	9
143	Rethinking Alzheimer's Disease. Frontiers in Neurology, 2012, 3, 45.	1.1	8
144	Mental time travel in mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 845-855.	0.8	8

#	Article	IF	Citations
145	Disease-related cortical thinning in presymptomatic granulin mutation carriers. Neurolmage: Clinical, 2021, 29, 102540.	1.4	8
146	Memory complaints in amnestic Mild Cognitive Impairment: More prospective or retrospective?. International Journal of Geriatric Psychiatry, 2018, 33, 1011-1018.	1.3	7
147	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 158-168.	0.9	7
148	<i>SLITRK2</i> , an X-linked modifier of the age at onset in <i>C9orf72</i> frontotemporal lobar degeneration. Brain, 2021, 144, 2798-2811.	3.7	7
149	Concluding Remarks. Journal of Alzheimer's Disease, 2010, 20, S249-S252.	1.2	7
150	Dataâ€driven staging of genetic frontotemporal dementia using multiâ€modal <scp>MRI</scp> . Human Brain Mapping, 2022, 43, 1821-1835.	1.9	7
151	Long-term depression is not modulated by ATP receptors in the rat CA1 hippocampal region. Neuroscience Letters, 2005, 383, 345-349.	1.0	6
152	Class Imbalance in the Prediction of Dementia from Neuropsychological Data. Lecture Notes in Computer Science, 2013, , 138-151.	1.0	6
153	Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 785-796.	1.2	6
154	Improving Prognostic Prediction from Mild Cognitive Impairment to Alzheimer's Disease Using Genetic Algorithms. Advances in Intelligent Systems and Computing, 2017, , 180-188.	0.5	6
155	Sustaining prospective memory functioning in amnestic mild cognitive impairment: A lifespan approach to the critical role of encoding Neuropsychology, 2018, 32, 634-644.	1.0	6
156	An exploration of prospective memory components and subtasks of the Memory for Intentions Test (MIST). Journal of Clinical and Experimental Neuropsychology, 2020, 42, 274-284.	0.8	5
157	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2021, 79, 163-175.	1.2	5
158	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.5	5
159	Can Subjective Memory Complaints Identify ${\rm Al}^2$ Positive and ${\rm Al}^2$ Negative Amnestic Mild Cognitive Impairment Patients?. Journal of Alzheimer's Disease, 2019, 70, 1103-1111.	1.2	4
160	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	3.0	4
161	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	1.5	3
162	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	1.2	3

#	Article	IF	Citations
163	Different MMSE domains are associated to cognitive decline and education. Applied Neuropsychology Adult, 2022, , 1-7.	0.7	3
164	Memory awareness in patients with Major Depressive Disorder. Journal of Psychiatric Research, 2021, 137, 411-418.	1.5	2
165	Shift of musical hallucinations to visual hallucinations after correction of the hearing deficit in a patient with Lewy body dementia: a case report. Journal of Medical Case Reports, 2021, 15, 449.	0.4	2
166	Towards Trustworthy Predictions of Conversion from Mild Cognitive Impairment to Dementia: A Conformal Prediction Approach. Advances in Intelligent Systems and Computing, 2017, , 155-163.	0.5	2
167	The Outcome of Patients with Amyloid-Negative Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2022, 86, 629-640.	1.2	2
168	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	1.1	2
169	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 336-339.	0.9	1
170	Prediction of Dementia Patients: A Comparative Approach Using Parametric Versus Nonparametric Classifiers. Studies in Theoretical and Applied Statistics, Selected Papers of the Statistical Societies, 2013, , 269-280.	0.2	1
171	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
172	Time perspective and amnestic mild cognitive impairment. Journal of Neuropsychology, 2022, 16, 463-480.	0.6	1
173	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332.	1.8	1
174	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	1.7	1
175	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.4	1
176	Control of NMDA receptors by adenosine: A new connection between coffee and excitation?. NeuroReport, 1995, 6, 1079.	0.6	0
177	[P4–071]: EXOME SEQUENCING IN ATYPICAL FRONTOTEMPORAL DEMENTIA WITH PERIâ€ROLANDIC ATROPHY SUGGESTS A ROLE FOR MATRIX METALLOPROTEINASES IN FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1285.	0.4	0
178	[ICâ€03–04]: WHITE MATTER HYPERINTENSITIES IN GENETIC FRONTOTEMPORAL DEMENTIA: A GENFI STUDY. Alzheimer's and Dementia, 2017, 13, P9.	0.4	0
179	Adenosine Receptors and Memory Disorders. , 2017, , 175-186.		0
180	Trajectory of apathy, cognition and neural correlates in the decades before symptoms in frontotemporal dementia. Alzheimer's and Dementia, 2020, 16, e041821.	0.4	0

#	Article	IF	CITATIONS
181	Aging and Cognitive Decline: Neuroprotective Strategies. , 2007, , 245-268.		0
182	Pattern of progression in MAPTâ€related frontotemporal dementia: Results from the GENFI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0